Which PET scan is better at spotting prostate cancer?

NCT ID NCT03604757

Completed Diagnosis Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two different radioactive tracers (68Ga-RM2 and 68Ga-PSMA-617) used in PET/CT scans to see which one better detects prostate cancer in men scheduled for prostate removal surgery. Twenty-two men with low, intermediate, or high-risk prostate cancer received both scans. The goal was to compare how well each tracer highlights cancer cells, which could help doctors choose the best imaging method for planning treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-PSMA-617 and 68Ga-RM2 (radioactive tracers for PET/CT imaging)
What this could lead to: If successful, this could help doctors choose the best imaging method to detect prostate cancer spread before surgery, improving treatment planning.
What could go wrong: This is a small, early-phase study with only 22 participants, so results may not apply to all patients. The tracers are used only for imaging, not treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Bordeaux University Hospital

Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.